carboxymethyl-beta-cyclodextrin and Neoplasms

carboxymethyl-beta-cyclodextrin has been researched along with Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for carboxymethyl-beta-cyclodextrin and Neoplasms

ArticleYear
Multifunctional nanoparticles of paclitaxel and cyclodextrin-polypeptide conjugates with
    Pharmaceutical development and technology, 2020, Volume: 25, Issue:9

    In this study, the cyclodextrin polypeptide (R8-CMβCD) was successfully synthesized by the conjugation of a cell-penetrating peptide (R8) with carboxymethyl-β-cyclodextrin (CMβCD) via the carbon diamine reaction. Then, paclitaxel-loaded nanoparticles (PTX@R8-CMβCD NPs) was prepared. Results of transmission electron microscopy (TEM) showed that PTX@R8-CMβCD NPs were spherical with smooth surfaces and an average diameter about 144 nm. The amount of PTX released from NPs was less than 20% at pH7.4, but it increased significantly to 80% in the weakly acidic cytoplasm of tumors (pH5.0). Furthermore, PTX@R8-CMβCD NPs promoted the cellular uptake of PTX. Further studies on the mechanism showed that cellular uptake of PTX@R8-CMβCD NPs could rely on multiple pathways. In addition, the NPs had the ability to inhibit P-gp efflux pumps. Cytotoxicity tests showed that the NPs had no side effects. Taken together, PTX@R8-CMβCD NPs is an effective anticancer drug delivery system, and the material (R8-CMβCD) may be a promising anti-cancer drug carrier.

    Topics: Animals; Antineoplastic Agents; beta-Cyclodextrins; Cell Line; Cell Line, Tumor; Cell-Penetrating Peptides; Cyclodextrins; Drug Delivery Systems; HEK293 Cells; Humans; MCF-7 Cells; Mice; Multifunctional Nanoparticles; Neoplasms; Paclitaxel; Peptides

2020